Samsung Bioepis to Present Post-hoc Analysis of Phase 3
Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May ...
Source: globenewswire.com
Jun Ho Jang News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jun Ho Jang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jun Ho Jang Today - Breaking & Trending Today
Eculizumab Biosimilar Comparable for Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria
These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.
Source: hcplive.com
Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia
The novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who did not respond or relapsed after at least 1 prior therapy.
Source: onclive.com
EHA 2023 Late-Breaking Abstracts Offer Sneak Peek at the Future of Hematology
The late-breaking oral session at the European Hematology Association (EHA) 2023 Congress featured newly emerged data from abstracts submitted after the deadline, including outcomes from trials in polycythemia vera, acute myeloid leukemia, and more.
Source: ajmc.com
Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed Biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022
Phase 3 study demonstrated clinical equivalence in efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of SB12 compared to reference eculizumab in paroxysmal nocturnal hemoglobinuria
Source: finanznachrichten.de